Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
284.25 -0.48 (-0.17%) 04/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 284.25 unch (unch) 16:01 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
281.41
Day High
291.11
Open 285.57
Previous Close 284.73 284.73
Volume 338,600 338,600
Avg Vol 458,505 458,505
Stochastic %K 37.88% 37.88%
Weighted Alpha +2.35 +2.35
5-Day Change +3.09 (+1.10%) +3.09 (+1.10%)
52-Week Range 233.27 - 417.82 233.27 - 417.82
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,787,791
  • Shares Outstanding, K 44,912
  • Annual Sales, $ 2,877 M
  • Annual Income, $ 1,195 M
  • EBIT $ 1,377 M
  • EBITDA $ 1,450 M
  • 60-Month Beta 0.63
  • Price/Sales 4.45
  • Price/Cash Flow 10.04
  • Price/Book 1.98

Options Overview Details

View History
  • Implied Volatility 44.41% ( +1.05%)
  • Historical Volatility 36.57%
  • IV Percentile 97%
  • IV Rank 73.78%
  • IV High 52.79% on 04/08/25
  • IV Low 20.82% on 05/09/24
  • Put/Call Vol Ratio 15.27
  • Today's Volume 244
  • Volume Avg (30-Day) 372
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 4,763
  • Open Int (30-Day) 4,438

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 6.29
  • Number of Estimates 8
  • High Estimate 7.07
  • Low Estimate 5.76
  • Prior Year 6.17
  • Growth Rate Est. (year over year) +1.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
266.98 +6.47%
on 04/09/25
Period Open: 312.99
322.32 -11.81%
on 03/25/25
-28.74 (-9.18%)
since 03/21/25
3-Month
266.98 +6.47%
on 04/09/25
Period Open: 367.97
383.51 -25.88%
on 02/19/25
-83.72 (-22.75%)
since 01/21/25
52-Week
233.27 +21.85%
on 04/24/24
Period Open: 237.93
417.82 -31.97%
on 11/08/24
+46.32 (+19.47%)
since 04/19/24

Most Recent Stories

More News
2 of Wall Street’s Favorite Stocks to Target This Week and 1 to Question

2 of Wall Street’s Favorite Stocks to Target This Week and 1 to Question

EPC : 30.01 (-0.10%)
KRT : 24.40 (+0.04%)
UTHR : 284.25 (-0.17%)
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

BMRN : 58.65 (-0.88%)
VRTX : 477.52 (-2.37%)
MRNA : 25.13 (+1.68%)
UTHR : 284.25 (-0.17%)
BIIB : 116.49 (-1.79%)
3 Reasons Investors Watch United Therapeutics (UTHR)

3 Reasons Investors Watch United Therapeutics (UTHR)

UTHR : 284.25 (-0.17%)
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

BMRN : 58.65 (-0.88%)
VRTX : 477.52 (-2.37%)
MRNA : 25.13 (+1.68%)
UTHR : 284.25 (-0.17%)
BIIB : 116.49 (-1.79%)
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off

2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off

CHE : 563.62 (-3.11%)
HIMS : 25.84 (-5.10%)
UTHR : 284.25 (-0.17%)
2 Value Stocks on Our Watchlist and 1 to Ignore

2 Value Stocks on Our Watchlist and 1 to Ignore

DHI : 120.76 (-0.40%)
UTHR : 284.25 (-0.17%)
PRKS : 43.10 (-2.88%)
Why United Therapeutics (UTHR) Stock Is Down Today

Why United Therapeutics (UTHR) Stock Is Down Today

UTHR : 284.25 (-0.17%)
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations

United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations

UTHR : 284.25 (-0.17%)
United Therapeutics: Q4 Earnings Snapshot

United Therapeutics: Q4 Earnings Snapshot

UTHR : 284.25 (-0.17%)
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

MYGN : 7.40 (-3.14%)
BMRN : 58.65 (-0.88%)
UTHR : 284.25 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 299.47
2nd Resistance Point 295.29
1st Resistance Point 289.77
Last Price 284.25
1st Support Level 280.07
2nd Support Level 275.89
3rd Support Level 270.37

See More

52-Week High 417.82
Fibonacci 61.8% 347.32
Fibonacci 50% 325.54
Fibonacci 38.2% 303.77
Last Price 284.25
52-Week Low 233.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro